Night blindness and blurred vision, the early symptoms of RP, are reported as side effects in human anti-tumor clinical trials of 17-DMAG, a synthetic Hsp90 inhibitor of geldanamycin derivative (Kummar et al., 2010; Pacey et al., 2011). Here, HSP90AA1 is linked to retinitis pigmentosa 1.